Abstract
The present article analyzes the epidemiology of chronic kidney disease (CKD), with emphasis on stage 5 CKD treated with periodic hemodialysis schedules. The physiopathology of potassium in renal patients under hemodialysis, as well as diagnosis of hyperpotassemia, whether acute or toxic, and the therapeutic approach to this disorder are discussed. We describe the acute therapeutic management of hyperpotassemia in chronic patients included in a dialysis program and discuss the particular features of the prescription of hemodialysis, insulin, albuterol, bicarbonate solution, intravenous calcium and resin therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
